![Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC](https://oncodaily.com/pub/uploads/2024/04/nejm.jpeg)
Photo taken from
Rami Manochakian/X
Apr 13, 2024, 09:40
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X:
“Hot off the press.
Just published at NEJM.
Results of ALINA phase 3 trial of adjuvant Alectinib vs Chemotherapy in patients with resected ALK+ stage IB-IIIA Non-Small-Cell Lung Cancer showing: DFS HR: 0.24
2-year DFS: 93% vs 63%”
Source: Rami Manochakian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 10, 2025, 18:24
Feb 10, 2025, 18:17
Feb 10, 2025, 16:49
Feb 10, 2025, 16:08
Feb 10, 2025, 15:56